Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IB/II open-label study of SHR-A2102 + Adebrelimab + SHR-8068 in locally advanced or metastatic non-small cell lung cancer
CTR20243391Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Oct 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-A2102 in non-small cell lung cancer (NSCLC), sponsored by Hengrui Therapeutics. Started Oct 2024; status: active.
02
Drugs
SHR-A2102
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20243391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243391.